Streetwise Regenerative Medicine Articles


Groundbreaking Biotech Company Takes Major Step Forward with Deal with Chinese Partner

  ()
Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the skin and tendon rejuvenation space. read more >
News Update

Cell Therapy Company and Chinese Firm Sign Marketing Deal

  ()
This biotech, in Phase 1 development of regenerative technologies addressing skin and orthopedic indications, has finalized a commercialization deal with YOFOTO. read more >

Target Price Increased on Biotech After Q2/18 Revenue Record, Beat

Research Report
  ()
A Maxim Group report explained the likely reasons behind revenue growth for the firm, which produces media used in development of cell therapies. read more >
Showing Results: 1 to 3 of 3

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"DRRX intends to start a NASH trial as soon as H1/19." ❭
– Francois Brisebois, Laidlaw & Company
"PMN is looking to outlicense PMN310 after the Phase 1 study." ❭
– André Uddin, Mackie Research Capital
"VIVs recent distribution deals illustrate demand for its technology." ❭
– Alex Koyfman, First Call